172 related articles for article (PubMed ID: 8004758)
81. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
82. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
83. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
84. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
85. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
[TBL] [Abstract][Full Text] [Related]
86. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
87. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
88. Small cell lung cancer and topoisomerases.
Giaccone G
Anticancer Res; 1994; 14(1B):269-76. PubMed ID: 8166466
[TBL] [Abstract][Full Text] [Related]
89. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
90. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Jun; 46(3):203-12. PubMed ID: 1354408
[TBL] [Abstract][Full Text] [Related]
91. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Fernandes DJ; Danks MK; Beck WT
Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
[TBL] [Abstract][Full Text] [Related]
92. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
93. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
[TBL] [Abstract][Full Text] [Related]
94. Phorbol regulation of topoisomerases I and II in human leukemia cells. Studies in an additional cell pair sensitive or resistant to phorbol-induced differentiation.
Ellis AL; Altschuler E; Bales E; Hinds M; Mayes J; Soares L; Zipf TF; Zwelling LA
Biochem Pharmacol; 1994 Jan; 47(2):387-96. PubMed ID: 8304982
[TBL] [Abstract][Full Text] [Related]
95. Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
Yamazaki K; Isobe H; Hanada T; Sukoh N; Ogura S; Kawakami Y
Acta Oncol; 1996; 35(4):417-23. PubMed ID: 8695154
[TBL] [Abstract][Full Text] [Related]
96. Topoisomerase expression in cancer cell lines and clinical samples.
Doyle LA
Cancer Chemother Pharmacol; 1994; 34 Suppl():S32-40. PubMed ID: 8070025
[TBL] [Abstract][Full Text] [Related]
97. Apoptosis induced by etoposide in small-cell lung cancer cell lines.
Okamoto-Kubo S; Nishio K; Heike Y; Yoshida M; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1994; 33(5):385-90. PubMed ID: 8306412
[TBL] [Abstract][Full Text] [Related]
98. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue.
Keith WN; Tan KB; Brown R
Genes Chromosomes Cancer; 1992 Mar; 4(2):169-75. PubMed ID: 1373318
[TBL] [Abstract][Full Text] [Related]
99. Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response.
Shen JW; Subjeck JR; Lock RB; Ross WE
Mol Cell Biol; 1989 Aug; 9(8):3284-91. PubMed ID: 2552289
[TBL] [Abstract][Full Text] [Related]
100. Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells.
Palaniyandi K; Zhao Q; Chang XB
Int J Biochem Mol Biol; 2011; 2(2):155-167. PubMed ID: 21968975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
